SCHEMBL12009749

SCHEMBL12009749

CC(=O)NC1C(C)OC(CO)C(O)C1OC1OC(C(=O)O)C(C)C(O)C1O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.46
▸ LGALS3 P17931 6/20 0.45
▸ LGALS8 O00214 1/20 0.45
▸ LGALS4 P56470 1/20 0.45
▸ CD69 Q07108 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ CHIA Q9BZP6 1/20 0.39
▸ MDK P21741 2/20 0.39
▸ PTN P21246 1/20 0.39
▸ BDNF P23560 1/20 0.39
▸ LGALS1 P09382 1/20 0.38
▸ LGALS7; LGALS7B P47929 1/20 0.38
▸ LGALS9 O00182 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15198764 0.92 LGALS3 (0.49) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL16269844 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL12580124 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL22112013 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL16085016 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL25024651 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL26842303 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL12552832 0.92 LGALS3 (0.48) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL19675783 0.91 MAPK1 (0.57) MAPK1LGALS3LGALS8LGALS4CD69
SCHEMBL18376688 0.91 MAPK1 (0.57) MAPK1LGALS3LGALS8LGALS4CD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170209360-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES L'OREAL (FR) 2017-07-27 — — US disclosed
US-8252348-B2 Cosmetic preparation comprising hyaluronic acid BEIERSDORF AG (DE) 2012-08-28 — — US disclosed
US-20080306021-A1 Cosmetic Preparation Comprising Hyaluronic Acid BEIERSDORF AG (DE) 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306021-A1 Cosmetic Preparation Comprising Hyaluronic Acid CD44, H1-5, H1-0 MAPK1 2017/4885LGALS3 198/4885LGALS8 144/4885
US-20170209360-A1 COSMETIC PROCESS FOR ATTENUATING WRINKLES CUTA, MC1R, GLA MAPK1 1950/4885LGALS3 89/4885LGALS8 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback